Sep 2026
Abstract A011: Targeting tumor-associated macrophage vulnerabilities to enhance therapy in pancreatic cancer
PDAC chemotherapy, including standard-of-care gemcitabine (GEM)/nab-paclitaxel (NP) regimen, is associated with the accumulation of TAMs that are functionally linked to therapeutic resistance and worse prognosis. GEM, but not NP, drives TAM polarization toward an immunosuppressive, M2-like phenotype characterized...
M. Romano, Makenna May, L. Pike et al.
· Cancer Research · 0 citations